XML 64 R28.htm IDEA: XBRL DOCUMENT v3.20.4
INTANGIBLE ASSETS, NET (Tables)
 12 Months Ended
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019:

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2020 and 2019:

 

                 
   December 31, 2020 
   Gross
Carrying
Amount		   Accumulated
Amortization		   Net
Amount		  

Weighted-

Average
Remaining

Amortization

Period (yrs.)

 
Amortizable intangible assets:                    
Approved hormone therapy drug candidate patents  $4,044,552   $(748,627)  $3,295,925    12 
Hormone therapy drug candidate patents (pending)   1,628,457    —    1,628,457    n/a 
Non-amortizable intangible assets:                    
   Multiple trademarks   323,341    —    323,341    indefinite 
TOTAL  $5,996,350   $(748,627)  $5,247,723      

 

                 
   December 31, 2019 
   Gross
Carrying
Amount		   Accumulated
Amortization		   Net
Amount		  

Weighted-

Average
Remaining

Amortization

Period (yrs.)

 
Amortizable intangible assets:                    
Approved hormone therapy drug candidate patents  $3,463,082   $(478,983)  $2,984,099    13 
Hormone therapy drug candidate patents (pending)   1,979,299    —    1,979,299    n/a 
Non-amortizable intangible assets:                    
   Multiple trademarks   294,813    —    294,813    indefinite 
TOTAL  $5,737,194   $(478,983)  $5,258,211      
Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:

Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:

 

Year Ending December 31,   Estimated Amortization 
2021   $274,669 
2022   $274,669 
2023   $274,669 
2024   $274,669 
2025   $274,669